Home › Funds › Frazier Life Sciences Management, L.P. › LXEO

Frazier Life Sciences Management, L.P. position in LXEO

LEXEO THERAPEUTICS INC COM · Health Care

Frazier Life Sciences Management, L.P. reported holding 4,824,725 shares of LXEO (LEXEO THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$22.5M, representing 0.49% of its reported portfolio and ranking #33 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed LXEO holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)4.82M sh
Reported value held$22.46M
Portfolio Weight0.49%
First reportedQ3 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s LXEO position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in LXEO in Q3 2024 at 1,250,786 shares (US$11.3M). The position peaked in Q4 2025 at 4,424,725 shares, worth US$43.9M. Across 8 filings, Frazier Life Sciences Management, L.P. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 4,824,725 shares valued at US$22.5M — an increase of 400,000 shares quarter over quarter.. Notable position changes include a 363% increase in Q2 2025 (shares rose 65% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 1.25M $11.31M New
Q4 2024 955.51K $6.29M Reduce
Q1 2025 955.51K $3.32M Hold
Q2 2025 4.42M $17.79M Add
Q3 2025 4.42M $29.38M Hold
Q4 2025 4.42M $43.94M Hold
Q1 2026 4.42M $25.40M Hold
Q2 2026 4.82M $22.46M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXEO and 13F data

LXEO (LEXEO THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Vestal Point Capital, LP (US$20.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXEO

All LXEO fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held LXEO?

Frazier Life Sciences Management, L.P. has disclosed LXEO holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is Frazier Life Sciences Management, L.P.'s current position in LXEO?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 4.82M shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $22.46M, representing 0.49% of its reported portfolio and ranking #33.

Has Frazier Life Sciences Management, L.P. been buying or selling LXEO?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. increased its position in LXEO. The position peaked in Q4 2025 at 4.42M shares.

Which other funds hold LXEO?

Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Vestal Point Capital, LP, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.